Review engagement letter template for SSARS reviews (AR-C 90)
Agree the terms of a review of financial statements in writing before the work starts, with management's responsibilities and the limits of a review set out in full. This review engagement letter template is one Word letter with every term AR-C section 90 lists, wording for GAAP or a special purpose framework, and a signature block for the entity.
US firmsGet this pack and 51 more for $79
Want every pack, for every region? Global library, 110 packs, $99
What the letter looks like

When to send it
AR-C section 90 requires you to agree the terms of a review with management or those charged with governance and to document them in an engagement letter or other written agreement. An oral understanding is not enough. The letter is signed by your firm and by management or those charged with governance. Send it when:
- A lender or other user asks the client for reviewed financial statements
- A client moves up from a compilation, or down from an audit, to a review
- A third party has contracted for the review: you still agree the terms with the entity's management
- The framework, the period or the fee changes for a continuing client
How to use the review engagement letter template
- Check independence first. A review needs you to be independent of the entity. If independence is impaired during the work, you withdraw.
- Fill in the entity, period and framework. GAAP or a special purpose framework. Keep the special purpose wording only if it applies.
- List the statements covered. Balance sheet, income, equity and cash flows, and the notes, with the right equity wording for a corporation or an LLC.
- Set the fee. Add the billing terms and keep the hourly rate line if extra work is likely.
- Get it signed before you start. Your firm signs, then management or those charged with governance sign the agreement block.
- Send the representation letter near the end. The client's representations are dated as of your review report.
Questions
What is a review engagement?
A review of financial statements under SSARS in which the accountant performs mainly analytical procedures and inquiries to obtain limited assurance, and reports whether they are aware of any material modifications needed for the statements to follow the framework. There is no opinion.
What must a review engagement letter include?
AR-C 90 lists the terms: the objectives of the engagement, management's responsibilities, the accountant's responsibilities, the limitations of a review including that it is substantially less in scope than an audit and that no opinion is expressed, the financial reporting framework, and the expected form and content of the report with a statement that it may differ.
Who signs a review engagement letter?
The accountant or the accountant's firm, and management or those charged with governance, as appropriate. Even when the terms are agreed with those charged with governance, management must still acknowledge its responsibilities.
Can the terms of a review be agreed orally?
No. AR-C 90 requires the understanding to be documented, and an oral understanding is not enough. An engagement letter is the most common way to document it.
Does the accountant need to be independent for a review?
Yes. The accountant must be independent of the entity to perform a review under SSARS, and must withdraw if independence becomes impaired during the engagement.
What responsibilities must management accept before a review?
Fair presentation under the framework with all informative disclosures, choosing the framework, internal control, preventing and detecting fraud, compliance with laws, accurate and complete information, access to people and records, a representation letter at the end, and including the review report in any document that says the statements were reviewed.
Also in the compilation and review engagement pack
Who it's for
US CPA firms that perform SSARS reviews of financial statements for private companies, nonprofits and other clients.
Last checked
Checked against AR-C section 90 as currently effective, including SSARS No. 25 and No. 26, in November 2026.
